Key points are not available for this paper at this time.
Introduction there were fewer SMBG in months 4-6 (1.0 0.0-4.3), 7-9 (0.0 0.0-2.3), and 10-12 (0.0 0.0-2.0) (p0.0001). Conclusion: Use of devices with remote data transfer is one potential tactic to support clinicians in conducting early-stage T1D monitoring. Strategies to sustain engagement are needed; qualitative studies may provide insight into barriers. Disclosure M.E. Pauley: None. C. Geno Rasmussen: None. K.A. Bautista: None. M. Munoz: None. I. Taki: None. F. Sepulveda: None. J. Baxter: None. M. Rewers: Advisory Panel; Sanofi. Other Relationship; Sanofi. Consultant; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Consultant; Provention Bio, Inc. Research Support; Hemsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases. K.M. Simmons: Advisory Panel; Provention Bio, Inc. Consultant; Provention Bio, Inc. Research Support; Provention Bio, Inc., Novartis AG. Consultant; Medtronic. Funding JDRF (2-SRA-2022-1270-S-B); NIH NIDDK (T325T32DK063687); DiabDocs Physician-Scientist Career Development Award: NIH NIDDK (K12DK133995) & The Leona M. and Harry B. Helmsley Charitable Trust to Stanford University (2305-06041)
PAULEY et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: